Clinical Trial Update: Regenecare® Wound Gel in Treating Rash in Patients Receiving Cetuximab or Other Epidermal Growth Factor Receptor Inhibitor Therapy for Cancer [NA]

View source ↗

Summary

A clinical trial update examines Regenecare Wound Gel for treating rash in cancer patients receiving EGFR inhibitors like cetuximab; the trial status is current…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer

Drugs mentioned

• Regenecare Wound Gel

Snippet

Sponsor: Ingalls Memorial Hospital | Conditions: Dermatologic Complications, Unspecified Adult Solid Tumor, Protocol Specific | NA | Status: UNKNOWN